Alkem Laboratories Limited — Q4 FY24
Alkem Laboratories reported Q4 FY24 PAT of INR 294 crore, impacted by a deferred tax derecognition of INR 120 crore.
bullish
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY24
Full-year EBITDA margin guidance of ~17%
Management expects FY24 EBITDA margin around 17%, with Q4 seasonally weaker but sustainable at that level.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY24
Enzene biosimilar breakeven this year
Biosimilar subsidiary Enzene expected to achieve breakeven in FY24 with revenue run-rate of ~₹200 Cr.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1